Treatment of antibody immunodeficiency

Česká verzia

Authors: Jiří Litzman
Authors place of work: Ústav klinické imunologie a alergologie LF MU a FN u sv. Anny v Brně
Published in the journal: Vnitř Lék 2019; 65(2): 126-130
Category:

Summary

The basis of treatment of patients with hypogammaglobulinemia, primary or secondary, is immunoglobulin replacement. Current immunoglobulin derivates contain highly purified IgG from healthy human donors. Intravenous or subcutaneous route are almost exclusively used at present. The treatment must be individualized. Adequate doses of immunoglobulin derivates must be administered to avoid frequent and severe infections of the respiratory tract. Antibiotic prophylaxis may be alternative and complementary treatment to immunoglobulin substitution.

Keywords:

Antibiotic prophylaxis – antibody immunodeficiency – immunoglobulin replacement treatment

Zdroje

Dhalla F, Misbah SA. Secondary antibody deficiencies. Curr Opin Allergy Clin Immunol 2015; 15(6): 505–513. Dostupné z DOI: <http://dx.doi.org/10.1097/ACI.0000000000000215>.
Bonilla FA, Barlan I, Chapel H et al. International Consensus Document (ICON): Common Variable Immunodeficiency Disorders. J Allergy Clin Immunol Pract 2016; 4(1): 38–59. Dostupné z DOI: <http://dx.doi.org/10.1016/j.jaip.2015.07.025>.
Chapel H, Cunningham-Rundles C. Update in understanding common variable immunodeficiency disorders (CVIDs) and the management of patients with these conditions. Br J Haematol 2009; 145(6): 709–727. Dostupné z DOI: <http://dx.doi.org/10.1111/j.1365–2141.2009.07669.x>.
Gathmann B, Mahlaoui N, Gérard L et al. Clinical picture and treatment of 2212 patients with common variable immunodeficiency. J Allergy Clin Immunol 2014; 134(1): 116–126. Dostupné z DOI: <http://dx.doi.org/10.1016/j.jaci.2013.12.1077>.
Ameratunga R, Woon ST, Gillis D et al. New diagnostic criteria for common variable immune deficiency (CVID), which may assist with decisions to treat with intravenous or subcutaneous immunoglobulin. Clin Exp Immunol 2013; 174(2): 203–211. Dostupné z DOI: <http://dx.doi.org/10.1111/cei.12178>.
Jolles S, Chapel H, Litzman J. When to initiate immunoglobulin replacement therapy (IGRT) in antibody deficiency: a practical approach. Clin Exp Immunol 2017; 188(3): 333–341. Dostupné z DOI: <http://dx.doi.org/10.1111/cei.12915>.
[Výbor České společnosti alergologie a klinické imunologie, Pracovní skupina pro primární imunodeficience]. Návrh standardu imunoglobulinové léčby nemocných s protilátkovými imunodeficienciemi. Alergie 2016; 18(1): 29–30.
Hoffman TW, van Kessel DA, van Velzen-Blad H et al. Antibody replacement therapy in primary antibody deficiencies and iatrogenic hypogammaglobulinemia. Expert Rev Clin Immunol 2015; 11(8): 921–933. Dostupné z DOI: <http://dx.doi.org/10.1586/1744666X.2015.1049599>.
Králíčková P. Současné formy imunoglobulinové substituční léčby. Alergie 2016; 18(2): 129–132.
Abolhassani H, Asgardoon MH, Rezaei N et al. Different brands of intravenous immunoglobulin for primary immunodeficiencies: how to choose the best option for the patient? Expert Rev Clin Immunol 2015; 11(11): 1229–1243. Dostupné z DOI: <http://dx.doi.org/10.1586/1744666X.2015.1079485>.
Maarschalk-Ellerbroek LJ, Hoepelman IM, Ellerbroek PM. Immunoglobulin treatment in primary antibody deficiency. Int J Antimicrob Agents 2011; 37(5): 396–404. Dostupné z DOI: <http://dx.doi.org/10.1016/j.ijantimicag.2010.11.027>.
Šutová I, Chovancová Z, Litzman J. Nežádoucí účinky imunoglobulinové léčby. Alergie 2018; 20(2): 123–128.
Berger M, Jolles S, Orange JS et al. Bioavailability of IgG administered by the subcutaneous route. J Clin Immunol 2013; 33(5): 984–990. Dostupné z DOI: <http://dx.doi.org/10.1007/s10875–013–9876–3>.
Hoffmann F, Grimbacher B, Thiel J et al. Home-based subcutaneous immunoglobulin G replacement therapy under real-life conditions in children and adults with antibody deficiency. Eur J Med Res 2010; 15(6): 238–245.
Shapiro RS. Subcutaneous immunoglobulin therapy given by subcutaneous rapid push vs infusion pump: a retrospective analysis. Ann Allergy Asthma Immunol 2013; 111(1): 51–55. Dostupné z DOI: <http://dx.doi.org/10.1016/j.anai.2013.04.015>.
Milota T, Šedivá A. Nové možnosti a perspektivy imunoglobulinové terapie. Alergie 2016; 18(4): 248–252.
Wasserman RL, Melamed I, Stein MR et al. Recombinant human hyaluronidase-facilitated subcutaneous infusion of human immunoglobulins for primary immunodeficiency. J Allergy Clin Immunol 2012; 130(4): 951–957. Dostupné z DOI: <http://dx.doi.org/10.1016/j.jaci.2012.06.021>.
Litzman J. Návrh standardu domácí imunoglobulinové léčby u pacientů s protilátkovým imunodeficitem. Alergie 2006; 8(1): 61–62.
Fasth A, Nyström J. Quality of life and health-care resource utilization among children with primary immunodeficiency receiving home treatment with subcutaneous human immunoglobulin. J Clin Immunol 2008; 28(4): 370–378. Dostupné z DOI: <http://dx.doi.org/10.1007/s10875–008–9180–9>.
Kittner JM, Grimbacher B, Wulff W et al. Patients‘ attitude to subcutaneous immunoglobulin substitution as home therapy. J Clin Immunol 2006; 26(4): 400–405. Dostupné z DOI: <http://dx.doi.org/10.1007/s10875–006–9031–5>.
Healey C, Chapel H. Intravenous immunoglobulin and hepatitis C virus: the British episode. Clin Ther 1996; 18: (Suppl B): 93–95.
Gelfand EW, Ochs HD, Shearer WT. Controversies in IgG replacement therapy in patients with antibody deficiency diseases. J Allergy Clin Immunol 2013; 131(4): 1001–1005. Dostupné z DOI: <http://dx.doi.org/10.1016/j.jaci.2013.02.028>.
Lucas M, Lee M, Lortan J et al. Infection outcomes in patients with common variable immunodeficiency disorders: relationship to immunoglobulin therapy over 22 years. J Allergy Clin Immunol 2010; 125(6): 1354–1360. Dostupné z DOI: <http://dx.doi.org/10.1016/j.jaci.2010.02.040>.
Kuruvilla M, de la Morena MT. Antibiotic prophylaxis in primary immune deficiency disorders. J Allergy Clin Immunol Pract 2013; 1(6): 573–582. Dostupné z DOI: <http://dx.doi.org/10.1016/j.jaip.2013.09.013>.
Doubková M, Moulis M, Skřičková J. Intersticiální Plicní procesy a granulomatózy asociované s běžným variabilním imunodeficitem. Vnitř Lék 2015; 61(2): 119–124.